AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04696341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
Study NCT00384293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: niacin (+) laropiprant (MK0524A)
Description: niacin (+) laropiprant (2 g) po qd.
Study NCT00384293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: niacin (+) laropiprant (2 g) placebo po qd.
Study NCT01862419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert
Study NCT05369091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10mg
Description: Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
Study NCT02406638 — intervention group
Intervention type: OTHER
Intervention: 3D pelvic floor ultrasound
Description: Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
Study NCT00007761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder Program
Study NCT00007761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual (psychiatric) Care
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
Study NCT02725424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
Study NCT00519922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthesia, Balance, and Agility (KBA) Exercise
Description: Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads.
Study NCT00519922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard LE Strength Training
Description: Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
Study NCT01419899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Description: A 20-30 minute motivational based discussion
Study NCT01758341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation
Description: Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
Study NCT01758341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
Study NCT01758341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabibTM EndoHPB catheter
Description: Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)
Study NCT01502124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
Study NCT01502124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
Study NCT01803269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT01803269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclodextrin-based polymer-camptothecin CRLX101
Description: Given IV
Study NCT03223909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-087
Description: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
Study NCT03223909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
Study NCT03223909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Preservative Free
Description: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
Study NCT03879096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise and Education
Description: Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
Study NCT01529931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go
Description: Hair2Go treatment once a month for 6 months
Study NCT01344616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle support
Description: computer-based lifestyle improvement support and clinician support
Study NCT04886557 — intervention group
Intervention type: PROCEDURE
Intervention: L4-L5 decompression and dynamic instrumentation
Description: All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
Study NCT01974882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
Study NCT02292121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a solution of mannitol and lactitol
Study NCT02292121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a solution of mannitol and lactitol
Study NCT01033760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine
Description: raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
Study NCT01033760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir; ritonavir; emtricitabine/tenofovir
Description: darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.0 ng/ml
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.4 ng/ml
Study NCT01056835 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: prostaglandin I2 analogue
Study NCT02026258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezotome-Corticision
Description: Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
Study NCT02026258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontics
Description: Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
Study NCT02026258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontics
Description: Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
Study NCT03321344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Thermal ablation
Description: Focused Ultrasound Thermal ablation of the Medial Nerve Branch
Study NCT02009735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virosensor
Description: virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
Study NCT00746330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MFF)
Description: Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.6 ng/ml
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 ng/ml Dexmedetomidine
Description: Dexmedetomidine target plasma concentration is 0.8 ng/ml
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
Study NCT02853864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
Study NCT00601757 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Postpartum Prevention Program (PPP)
Description: PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
Study NCT00601757 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced care as usual (ECU)
Description: ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
Study NCT04421092 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior laryngeal nerve block
Description: Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
Study NCT05010057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrants (NZBC)
Description: NZBC capsules containing anthocyanin-rich blackcurrant extract
Study NCT04421092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior laryngeal nerve block
Description: Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
Study NCT04421092 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo (saline)
Description: Superior laryngeal nerve block using 1mL of saline as the injection.
Study NCT04421092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of steroid-lidocaine mixture
Description: Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
Study NCT04625062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
Study NCT04625062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-based treatment
Description: Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
Study NCT03827018 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: 1 mL of 150 mg in a pre-filled syringe
Study NCT03827018 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL of placebo in a pre-filled syringe
Study NCT03827018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Study NCT03827018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Study NCT02524184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 100 mg per day for 7 days.
Study NCT02524184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an identical placebo per day for 7 days
Study NCT00986024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: carried out 3 times per week for 12 weeks
Study NCT00986024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: carried out 3 times per week for 12 weeks
Study NCT05342649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: P-CTG
Description: soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
Study NCT05342649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG
Description: soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
Study NCT01636284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594 recombinant vaccina GM-CSF
Description: Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
Study NCT00004466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT00004466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00949533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
Study NCT00949533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
Study NCT00156195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10 mg Tablet, oral Daily for 12 months
Study NCT00156195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 months
Study NCT03202394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIO-11006
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Study NCT03202394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Study NCT01597817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chitosan coated textile
Description: chitosan coated cotton long sleeved shirts and pants.
Study NCT01597817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chitosan free cotton long sleeved t-shirts and pants.
Description: chitosan free cotton long sleeved shirts and pants.
Study NCT00560417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Protamine Suspension
Description: Administered subcutaneously once a day at bedtime